Treatment of Melanoma with Agonist Immune Costimulatory Agents View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2011-11-13

AUTHORS

Andrew Weinberg , Robert H. Vonderheide , Mario Sznol

ABSTRACT

Immune therapy for melanoma is likely to be improved by better strategies to activate and expand tumor-specific T-cells, and to enhance their ability to infiltrate and function in the tumor microenvironment. In addition to or as an alternative to immunization with cancer antigens and administration of cytokines, antitumor T-cell responses can be positively modulated by activation of receptors that provide important dendritic cell (DC) maturation signals or T-cell costimulatory signals. At least three such stimulatory monoclonal antibodies, directed against OX40, CD137, and CD40, have been evaluated extensively in preclinical studies and have undergone at least preliminary evaluation in patients with metastatic melanoma. All three agents demonstrated limited but encouraging clinical antitumor activity in phase 1 trials. Future rational development of these agents will require a better understanding of the role of the receptors in evolving immune responses, the optimal timing and duration of administration in the context of the underlying host–tumor immune interactions, and the ability to combine the agents with each other and with other immunomodulators in appropriately selected patient populations. More... »

PAGES

307-331

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_16

DOI

http://dx.doi.org/10.1007/978-1-61779-407-0_16

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046333121


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Laboratory of Basic Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA", 
          "id": "http://www.grid.ac/institutes/grid.240531.1", 
          "name": [
            "Laboratory of Basic Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weinberg", 
        "givenName": "Andrew", 
        "id": "sg:person.01055232610.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055232610.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRB II/III, 421 Curie Boulevard, 19104, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRB II/III, 421 Curie Boulevard, 19104, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vonderheide", 
        "givenName": "Robert H.", 
        "id": "sg:person.01316235425.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316235425.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale Cancer Center, 333 Cedar Street, FMP #126, 208032, 06520, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Yale Cancer Center, 333 Cedar Street, FMP #126, 208032, 06520, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-11-13", 
    "datePublishedReg": "2011-11-13", 
    "description": "Immune therapy for melanoma is likely to be improved by better strategies to activate and expand tumor-specific T-cells, and to enhance their ability to infiltrate and function in the tumor microenvironment. In addition to or as an alternative to immunization with cancer antigens and administration of cytokines, antitumor T-cell responses can be positively modulated by activation of receptors that provide important dendritic cell (DC) maturation signals or T-cell costimulatory signals. At least three such stimulatory monoclonal antibodies, directed against OX40, CD137, and CD40, have been evaluated extensively in preclinical studies and have undergone at least preliminary evaluation in patients with metastatic melanoma. All three agents demonstrated limited but encouraging clinical antitumor activity in phase 1 trials. Future rational development of these agents will require a better understanding of the role of the receptors in evolving immune responses, the optimal timing and duration of administration in the context of the underlying host\u2013tumor immune interactions, and the ability to combine the agents with each other and with other immunomodulators in appropriately selected patient populations.", 
    "editor": [
      {
        "familyName": "Gajewski", 
        "givenName": "Thomas F.", 
        "type": "Person"
      }, 
      {
        "familyName": "Hodi", 
        "givenName": "F. Stephen", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-61779-407-0_16", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-61779-406-3", 
        "978-1-61779-407-0"
      ], 
      "name": "Targeted Therapeutics in Melanoma", 
      "type": "Book"
    }, 
    "keywords": [
      "host-tumor immune interactions", 
      "antitumor T-cell responses", 
      "tumor-specific T cells", 
      "T cell responses", 
      "phase 1 trial", 
      "duration of administration", 
      "T-cell costimulatory signals", 
      "clinical antitumor activity", 
      "administration of cytokines", 
      "treatment of melanoma", 
      "activation of receptors", 
      "stimulatory monoclonal antibody", 
      "immune therapy", 
      "patient population", 
      "metastatic melanoma", 
      "T cells", 
      "cancer antigens", 
      "preclinical studies", 
      "immune response", 
      "immune interactions", 
      "costimulatory signals", 
      "maturation signals", 
      "tumor microenvironment", 
      "optimal timing", 
      "monoclonal antibodies", 
      "costimulatory agents", 
      "antitumor activity", 
      "melanoma", 
      "administration", 
      "future rational development", 
      "receptors", 
      "agents", 
      "CD137", 
      "OX40", 
      "patients", 
      "immunomodulators", 
      "immunization", 
      "cytokines", 
      "rational development", 
      "CD40", 
      "therapy", 
      "antigen", 
      "trials", 
      "antibodies", 
      "response", 
      "treatment", 
      "best strategy", 
      "preliminary evaluation", 
      "microenvironment", 
      "duration", 
      "activation", 
      "better understanding", 
      "population", 
      "ability", 
      "evaluation", 
      "activity", 
      "study", 
      "role", 
      "timing", 
      "addition", 
      "strategies", 
      "development", 
      "alternative", 
      "understanding", 
      "signals", 
      "interaction", 
      "context"
    ], 
    "name": "Treatment of Melanoma with Agonist Immune Costimulatory Agents", 
    "pagination": "307-331", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046333121"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-61779-407-0_16"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-61779-407-0_16", 
      "https://app.dimensions.ai/details/publication/pub.1046333121"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_428.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-61779-407-0_16"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_16'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_16'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_16'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-407-0_16'


 

This table displays all metadata directly associated to this object as RDF triples.

151 TRIPLES      22 PREDICATES      91 URIs      84 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-61779-407-0_16 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author Nabca9dcd541f4c5aac3a93a9c9783246
4 schema:datePublished 2011-11-13
5 schema:datePublishedReg 2011-11-13
6 schema:description Immune therapy for melanoma is likely to be improved by better strategies to activate and expand tumor-specific T-cells, and to enhance their ability to infiltrate and function in the tumor microenvironment. In addition to or as an alternative to immunization with cancer antigens and administration of cytokines, antitumor T-cell responses can be positively modulated by activation of receptors that provide important dendritic cell (DC) maturation signals or T-cell costimulatory signals. At least three such stimulatory monoclonal antibodies, directed against OX40, CD137, and CD40, have been evaluated extensively in preclinical studies and have undergone at least preliminary evaluation in patients with metastatic melanoma. All three agents demonstrated limited but encouraging clinical antitumor activity in phase 1 trials. Future rational development of these agents will require a better understanding of the role of the receptors in evolving immune responses, the optimal timing and duration of administration in the context of the underlying host–tumor immune interactions, and the ability to combine the agents with each other and with other immunomodulators in appropriately selected patient populations.
7 schema:editor Ncb270d6e4fd640f48dff5ad6e698e3fd
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N97610651137746998a970a7ae57f281e
11 schema:keywords CD137
12 CD40
13 OX40
14 T cell responses
15 T cells
16 T-cell costimulatory signals
17 ability
18 activation
19 activation of receptors
20 activity
21 addition
22 administration
23 administration of cytokines
24 agents
25 alternative
26 antibodies
27 antigen
28 antitumor T-cell responses
29 antitumor activity
30 best strategy
31 better understanding
32 cancer antigens
33 clinical antitumor activity
34 context
35 costimulatory agents
36 costimulatory signals
37 cytokines
38 development
39 duration
40 duration of administration
41 evaluation
42 future rational development
43 host-tumor immune interactions
44 immune interactions
45 immune response
46 immune therapy
47 immunization
48 immunomodulators
49 interaction
50 maturation signals
51 melanoma
52 metastatic melanoma
53 microenvironment
54 monoclonal antibodies
55 optimal timing
56 patient population
57 patients
58 phase 1 trial
59 population
60 preclinical studies
61 preliminary evaluation
62 rational development
63 receptors
64 response
65 role
66 signals
67 stimulatory monoclonal antibody
68 strategies
69 study
70 therapy
71 timing
72 treatment
73 treatment of melanoma
74 trials
75 tumor microenvironment
76 tumor-specific T cells
77 understanding
78 schema:name Treatment of Melanoma with Agonist Immune Costimulatory Agents
79 schema:pagination 307-331
80 schema:productId N61b8794f42014d07af4fe1eb1851817d
81 N807131ef2ad8472393d6db7f0b139ea9
82 schema:publisher Na95d363ab76841c5bfe372ebbc7e4e88
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046333121
84 https://doi.org/10.1007/978-1-61779-407-0_16
85 schema:sdDatePublished 2022-09-02T16:16
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher N0a23744d1585449d9d79061144e4b98d
88 schema:url https://doi.org/10.1007/978-1-61779-407-0_16
89 sgo:license sg:explorer/license/
90 sgo:sdDataset chapters
91 rdf:type schema:Chapter
92 N0a23744d1585449d9d79061144e4b98d schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 N2168a16ec2794ef4a2803bf1a673f533 rdf:first sg:person.0706626451.72
95 rdf:rest rdf:nil
96 N245c719db4694f97b2400518f4ba4250 schema:familyName Gajewski
97 schema:givenName Thomas F.
98 rdf:type schema:Person
99 N50b6f58786ba4c289f897d57f676350d rdf:first sg:person.01316235425.61
100 rdf:rest N2168a16ec2794ef4a2803bf1a673f533
101 N61b8794f42014d07af4fe1eb1851817d schema:name doi
102 schema:value 10.1007/978-1-61779-407-0_16
103 rdf:type schema:PropertyValue
104 N807131ef2ad8472393d6db7f0b139ea9 schema:name dimensions_id
105 schema:value pub.1046333121
106 rdf:type schema:PropertyValue
107 N9499224fd7e248238cc25e65bfb1cfd3 rdf:first Ne5a20168bd0a4565b82258e2836c95cb
108 rdf:rest rdf:nil
109 N97610651137746998a970a7ae57f281e schema:isbn 978-1-61779-406-3
110 978-1-61779-407-0
111 schema:name Targeted Therapeutics in Melanoma
112 rdf:type schema:Book
113 Na95d363ab76841c5bfe372ebbc7e4e88 schema:name Springer Nature
114 rdf:type schema:Organisation
115 Nabca9dcd541f4c5aac3a93a9c9783246 rdf:first sg:person.01055232610.01
116 rdf:rest N50b6f58786ba4c289f897d57f676350d
117 Ncb270d6e4fd640f48dff5ad6e698e3fd rdf:first N245c719db4694f97b2400518f4ba4250
118 rdf:rest N9499224fd7e248238cc25e65bfb1cfd3
119 Ne5a20168bd0a4565b82258e2836c95cb schema:familyName Hodi
120 schema:givenName F. Stephen
121 rdf:type schema:Person
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
126 schema:name Immunology
127 rdf:type schema:DefinedTerm
128 sg:person.01055232610.01 schema:affiliation grid-institutes:grid.240531.1
129 schema:familyName Weinberg
130 schema:givenName Andrew
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055232610.01
132 rdf:type schema:Person
133 sg:person.01316235425.61 schema:affiliation grid-institutes:grid.25879.31
134 schema:familyName Vonderheide
135 schema:givenName Robert H.
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316235425.61
137 rdf:type schema:Person
138 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.433818.5
139 schema:familyName Sznol
140 schema:givenName Mario
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
142 rdf:type schema:Person
143 grid-institutes:grid.240531.1 schema:alternateName Laboratory of Basic Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA
144 schema:name Laboratory of Basic Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA
145 rdf:type schema:Organization
146 grid-institutes:grid.25879.31 schema:alternateName Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRB II/III, 421 Curie Boulevard, 19104, Philadelphia, PA, USA
147 schema:name Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRB II/III, 421 Curie Boulevard, 19104, Philadelphia, PA, USA
148 rdf:type schema:Organization
149 grid-institutes:grid.433818.5 schema:alternateName Yale Cancer Center, 333 Cedar Street, FMP #126, 208032, 06520, New Haven, CT, USA
150 schema:name Yale Cancer Center, 333 Cedar Street, FMP #126, 208032, 06520, New Haven, CT, USA
151 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...